Navigation Links
Drug Combo Staves Off Type 2 Diabetes
Date:6/2/2010

mum dose of the drug.

Findings from the study, which was funded by Avandia's maker, GlaxoSmithKline, were published in the June 3 online edition of The Lancet.

The trial included 207 adults with impaired glucose tolerance, sometimes called pre-diabetes. Not everyone with impaired glucose tolerance goes on to develop type 2 diabetes, but the condition is associated with long-term cardiovascular risks, according to Dr. Richard Bergenstal, president of medicine and science for the American Diabetes Association.

"Impaired glucose tolerance, although not labeled a disease, is not a benign condition," he said.

The current gold standard of treatment for pre-diabetes, according to Bergenstal, is lifestyle changes such as getting regular exercise and losing weight. And, when maintained, lifestyle changes can be very effective in preventing type 2 diabetes, but such changes aren't always maintained.

"Lifestyle changes have to be the basis for treating diabetes," concurred Zinman, "But, the number of people who implement those changes effectively is small. For someone to lose weight and maintain that weight loss is uncommon."

The study included a year of structured lifestyle intervention for all of the study volunteers. In addition, 103 study participants were given 2 milligrams (mg) of Avandia once a day and 500 mg of metformin twice daily, while 104 people were given placebo pills.

The average follow-up time was 3.9 years, and during that time 14 percent of the drug combo group developed type 2 diabetes, while 39 percent of the placebo group did.

That translates to a 66 percent reduced risk of progressing to diabetes for the treatment group, according to the study.

Additionally, 80 percent of those treated achieved normal blood sugar levels during the study compared to just 53 percent in the placebo group.

"It's critically important that we stem this epidemic of diabet
'/>"/>

Copyright©2010 ScoutNews,LLC.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Bone Marrow Cancer Patients May Benefit From Drug Combo
2. Short-Term Drug Combo May Help Prevent Colon Cancer
3. Drug Combo Blocks HIV Infection in Mice
4. Combo PET-CT Scans Can Spot Hidden Cancers
5. Blood Thinner Combos Risky for Heart Attack Patients
6. OrbusNeich Announces First Patient Enrolled in REMEDEE, a Randomized Clinical Trial of the Combo Bio-engineered Sirolimus Eluting Stent
7. CSHL scientists discover how a tumor suppressor induces senescence and staves off cancer
8. Nicer than needles: Insulin pills for diabetes finally in clinical trials
9. Just Graduated College Seniors Ride for Loved Ones With Diabetes Cycling Cross Country to Raise Funds to Help Find a Cure
10. Dieting alone may not help stave off type 2 diabetes; muscle mass, strength important
11. TransforMED's Delta-Exchange Teams with Group Practice Forum to Present Free Webinar Series on Diabetes Population Management
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... NY (PRWEB) , ... July 30, 2015 , ... ... and Sustamine® L-Alanyl-L-Glutamine for people on the go. With no water needed, the ... Chewable as a simple way to get the natural ingredients that may help ...
(Date:7/30/2015)... ... 2015 , ... Eyepartner is proud to highlight that their ... Gaslamp Quarter Plaza for five years this September. , The surveillance and ... any suspicious activity. These cameras are in place to provide inarguable proof in ...
(Date:7/30/2015)... ... 2015 , ... The American Telemedicine Association (ATA) is seeking ... exclusively on telemedicine, telehealth and mHealth. The meeting, expected to attract over 6,000 ... May 14-17, 2016 in Minneapolis, MN. , ATA’s annual meeting attracts the world’s ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... into one of the largest, family-owned low cost service and repair companies. For ... applications, as well as growing their company to meet the demands of the ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... throughout Orange, Riverside, Los Angeles, and San Bernardino counties, today announced that Dr. ... Palliative Care Administrator. Dr. Demoratz is a strong proponent of early access to ...
Breaking Medicine News(10 mins):Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 2Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 3Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 4Health News:Eyepartner Software Helps Victims in Gaslamp Quarter Plaza 2Health News:Eyepartner Software Helps Victims in Gaslamp Quarter Plaza 3Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 2Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 3Health News:Bill Howe Plumbing, Heating & Air Launches Online Application to Prospective Employees 2Health News:Bill Howe Plumbing, Heating & Air Launches Online Application to Prospective Employees 3Health News:24/7 Care At Home Welcomes Michael Demoratz, PhD, LCSW, CCM as New Palliative Care Administrator 2Health News:24/7 Care At Home Welcomes Michael Demoratz, PhD, LCSW, CCM as New Palliative Care Administrator 3
... ... has everything to do with the oil industry. Anyone who can understand this contradiction, will ... production systems should be a primary goal now, keeping BP’s oil spill and the effects ... ...
... study needs further testing in humans, experts say , SUNDAY, ... ubiquitous sugar known as fructose may cause certain fat cells ... role in childhood and adult obesity. , Fructose is a ... a variety of foods, including soft drinks, candy and many ...
... , ... prominent dentists and practitioners in all fields of the dental profession will come together to ... , ... 2010 -- This is the second in a series of unique conferences offering high-quality scientific ...
... ... specializing in skin care and plastic surgery celebrates its 10 year Anniversary. , ... (PRWEB) June 20, 2010 -- Having grown ... web, SignatureForum.com is proud to mark its 10th anniversary this summer by thanking ...
... ... redesigned its teaching clinic, SensAbility, with environmentally friendly selections including furnishings made with ... ... -- Atlanta School of Massage ( www.atlantaschoolofmassage.com ) and Atlanta Institute of Aesthetics ...
... factors may not develop the condition, study suggests , ... number of obese people, those extra pounds do not ... report. , For those few without other risk factors ... obese doesn,t raise their risk of cardiovascular trouble. , ...
Cached Medicine News:Health News:Wind turbines harmful for the environment and public health 2Health News:'Junk Food' Sugar May Help Some Fat Cells Proliferate 2Health News:'Junk Food' Sugar May Help Some Fat Cells Proliferate 3Health News:The 2nd Future Trends in Implantology International Dental Conference 2Health News:Signature Forum Celebrates 10th Anniversary 2Health News:Atlanta School of Massage Celebrates 30th Anniversary with a New Green Design and New Name for its Teaching Clinic: SensAbility 2Health News:Atlanta School of Massage Celebrates 30th Anniversary with a New Green Design and New Name for its Teaching Clinic: SensAbility 3Health News:Atlanta School of Massage Celebrates 30th Anniversary with a New Green Design and New Name for its Teaching Clinic: SensAbility 4Health News:Obesity Not Always a Sentence for Heart Disease 2Health News:Obesity Not Always a Sentence for Heart Disease 3
(Date:7/30/2015)...  Amgen (NASDAQ: AMGN ) today announced ... Key results include: , Total revenues increased ... to $5,370 million, with 6 percent product sales ... Prolia ® (denosumab), Sensipar ® (cinacalcet), ... (denosumab). Unfavorable changes in foreign exchange rates impacted ...
(Date:7/30/2015)... July 30, 2015 Tianyin Pharmaceutical Inc. (NYSE ... that specializes in the patented biopharmaceutical, modernized traditional Chinese ... provided updates regarding the notice it received on May ... indicating that the Company was below certain of the ... 134 and 1101 of the NYSE MKT Company Guide, ...
(Date:7/30/2015)... , July 30, 2015  Growth of the ... as they bring former prescription users to the OTC ... Kline forecasts robust Rx-to-OTC switch activity over the ... emerging along with many new brands entering the market ... over the next five years (even those with low ...
Breaking Medicine Technology:Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 3
... GUANGZHOU, China, Oct. 30 /PRNewswire-Asia/ -- ... Medicine" or "the Company"), a developer,and leading ... medicines ("TCM"), nutritional and dietary supplements,and medical ... through its,wholly-owned subsidiary in China, Konzern Pharmaceuticals, ...
... , TAIPEI, Taiwan, Oct. ... WHC,2009 in Beijing: from bench to bedside and ... management. This solution entails a series of,innovative ... screening, diagnosis, and treatment follow-up. Microlife successfully,developed ...
Cached Medicine Technology:China Medicine Corporation to Acquire Pharmaceutical Manufacturer in Guangzhou 2China Medicine Corporation to Acquire Pharmaceutical Manufacturer in Guangzhou 3China Medicine Corporation to Acquire Pharmaceutical Manufacturer in Guangzhou 4Microlife-WatchBP Series is Proud to Present its Total Concept at the World Hypertension Congress 2Microlife-WatchBP Series is Proud to Present its Total Concept at the World Hypertension Congress 3
VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (...
VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (...
VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (...
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),...
Medicine Products: